UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009690
Receipt number R000011362
Scientific Title Comparison of incretin-related drugs (GLP-1 receptor agonists and DPP IV inhibitors) and insulin for clinical effects in patients with type 2 diabetes mellitus
Date of disclosure of the study information 2013/01/04
Last modified on 2014/07/12 14:23:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of incretin-related drugs (GLP-1 receptor agonists and DPP IV inhibitors) and insulin for clinical effects in patients with type 2 diabetes mellitus

Acronym

Comparison of incretin-related drugs (GLP-1 receptor agonists and DPP IV inhibitors) and insulin for clinical effects in patients with type 2 diabetes mellitus

Scientific Title

Comparison of incretin-related drugs (GLP-1 receptor agonists and DPP IV inhibitors) and insulin for clinical effects in patients with type 2 diabetes mellitus

Scientific Title:Acronym

Comparison of incretin-related drugs (GLP-1 receptor agonists and DPP IV inhibitors) and insulin for clinical effects in patients with type 2 diabetes mellitus

Region

Japan


Condition

Condition

type 2 diabetes mellitus

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to assess the effect of therapy of liraglutide, alogliptin and glargine on glycemic control and clinical parameters in patients with type 2 diabetes

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

change of HbA1c and BW (body mass index)

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Single blind -participants are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

Numbered container method


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

liraglutide 0.6-0.9mg/day

Interventions/Control_2

alogliptin 25mg/day

Interventions/Control_3

glargine

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

HbA1c (JDS):7.0-11.0%
Type 2 diabetes
Patients with written informed consent

Key exclusion criteria

1)severe ketosis, diabetic coma within 6 months
2)severe infection, before operation, severe trauma
3)pregnacy
4)liver cirrhosis, chronic renal failure (serum creatinine level>2.0mg/dL), respiratory failure
5)allergy for liraglutide, alogliptin and glargine
6)patients judged by the investigator to be ineligible for some other reason

Target sample size

120


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kenta Okada

Organization

Jichi Medical University

Division name

Endocrinology and Metabolism

Zip code


Address

3311-1 Yakushiji, Shimotsuke-City, Tochigi, Japan

TEL

0285-44-2111

Email

kokada@jichi.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kenta Okada

Organization

Jichi Medical University

Division name

Endocrinology and Metabolism

Zip code


Address

3311-1 Yakushiji, Shimotsuke-City, Tochigi, Japan

TEL

0285-44-2111

Homepage URL


Email

kokada@jichi.ac.jp


Sponsor or person

Institute

Division of Endocrinology and Metabolism, Jichi Medical University

Institute

Department

Personal name



Funding Source

Organization

Division of Endocrinology and Metabolism, Jichi Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Nasuchuoh hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

B10-88

Org. issuing International ID_1

Jichi Medical University

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 01 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 06 Month 29 Day

Date of IRB


Anticipated trial start date

2011 Year 06 Month 29 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 01 Month 04 Day

Last modified on

2014 Year 07 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011362


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name